ConductScience.org, home

Paper35637990

Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis.

Dar S and 7 others. Ann Med Surg (Lond), 2022. Cited by 17 papers, by iCite.

Cite this record

ConductScience Library. Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis. Papers, record 35637990. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35637990

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis.
PubMed
Journal
Ann Med Surg (Lond)
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
17
iCite
Relative citation ratio, by iCite
1.31
iCite
Revised in PubMed
2022-07-16
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dar SSophia
2Siddiqi AKAhmed Kamal
3Alabduladhem TOTamim Omar
4Rashid AMAhmed Mustafa
5Sarfraz SSaba
6Maniya TTalha
7Menezes RGRitesh G
8Almas TTalal

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13802833Meta-analysis in clinical trials.Control Clin Trials1986https://conductscience.org/library/papers/3802833PubMed
229286050Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.Nat Rev Endocrinol2018https://conductscience.org/library/papers/29286050PubMed
328086872Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.Cardiovasc Diabetol2017https://conductscience.org/library/papers/28086872PubMed
428683796Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.Cardiovasc Diabetol2017https://conductscience.org/library/papers/28683796PubMed
528930295Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol2018https://conductscience.org/library/papers/28930295PubMed
625865049Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.Gastroenterology2015https://conductscience.org/library/papers/25865049PubMed
733520110Novel glucose-lowering drugs for non-alcoholic fatty liver disease.World J Diabetes2021https://conductscience.org/library/papers/33520110PubMed
834507895The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis.Dig Liver Dis2022https://conductscience.org/library/papers/34507895PubMed
934446261The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.Rev Esp Cardiol (Engl Ed)2021https://conductscience.org/library/papers/34446261PubMed
1032152903Epidemiology of non-alcoholic fatty liver disease in Asia.Indian J Gastroenterol2020https://conductscience.org/library/papers/32152903PubMed
1133035599Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.Diabetes Res Clin Pract2020https://conductscience.org/library/papers/33035599PubMed
1233789826The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.Int J Surg2021https://conductscience.org/library/papers/33789826PubMed
1332083798Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.J Diabetes Investig2020https://conductscience.org/library/papers/32083798PubMed
1430414863Non-alcoholic fatty liver disease - A global public health perspective.J Hepatol2019https://conductscience.org/library/papers/30414863PubMed
1517130197Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.Diabetes Care2006https://conductscience.org/library/papers/17130197PubMed
1624402015Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.Arq Bras Endocrinol Metabol2013https://conductscience.org/library/papers/24402015PubMed
1725554560Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.Clin Ther2015https://conductscience.org/library/papers/25554560PubMed
1832314464
Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB).
Diabetes Obes Metab2020https://conductscience.org/library/papers/32314464PubMed
1917157112
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Clin Ther2006https://conductscience.org/library/papers/17157112PubMed
2033396949Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.Metabolites2020https://conductscience.org/library/papers/33396949PubMed

See all 28 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.

PMIDTitleJournalYearIn PapersSource
42878985GLP-1 Receptor Agonists and Lipoprotein (a): Insights, Gaps and Clinical Implications in Cardiovascular Diseases.Curr Atheroscler Rep2026https://conductscience.org/library/papers/42878985PubMed
42794744Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome.Int J Mol Sci2026https://conductscience.org/library/papers/42794744PubMed
41143728Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus.Eur Heart J Cardiovasc Pharmacother2025https://conductscience.org/library/papers/41143728PubMed
40823521Outcomes of empagliflozin in nondiabetic fatty liver patients: A randomized controlled trial.J Taibah Univ Med Sci2025https://conductscience.org/library/papers/40823521PubMed
40652242
Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety.
Cardiovasc Diabetol2025https://conductscience.org/library/papers/40652242PubMed
40309616Patient Adherence for Oral Combination Therapies in Diabetes Management: A Scoping Review.Health Sci Rep2025https://conductscience.org/library/papers/40309616PubMed
39525721Novel FDA-approved bexagliflozin drug for treating type 2 diabetes mellitus.Ann Med Surg (Lond)2024https://conductscience.org/library/papers/39525721PubMed
39396983Association of plasma arachidonic acid levels with a bipolar disorder and the effects of a FADS gene variant.Transl Psychiatry2024https://conductscience.org/library/papers/39396983PubMed
39386037
Real-World Utilization and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Dosed Weekly and Daily in Patients with Type 2 Diabetes Mellitus: Results from Retrospective Electronic Medical Records in China.
Diabetes Metab Syndr Obes2024https://conductscience.org/library/papers/39386037PubMed
39201071
Retrospective Longitudinal Observational Study on the Long-Term Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Development of Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetic Japanese Patients.
J Clin Med2024https://conductscience.org/library/papers/39201071PubMed
38794138Classical and Novel Lipid-Lowering Therapies for Diabetic Patients with Established Coronary Artery Disease or High Risk of Coronary Artery Disease-A Narrative Clinical Review.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/38794138PubMed
38148417Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes.Curr Atheroscler Rep2024https://conductscience.org/library/papers/38148417PubMed
37635974Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/37635974PubMed
37373310Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets.Int J Mol Sci2023https://conductscience.org/library/papers/37373310PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
DPP41803PubTator's text mininghttps://conductscience.org/library/genes/1803NCBI Gene
EHMT179813PubTator's text mininghttps://conductscience.org/library/genes/79813NCBI Gene
GCG2641PubTator's text mininghttps://conductscience.org/library/genes/2641NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene
SLC5A26524PubTator's text mininghttps://conductscience.org/library/genes/6524NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35637990

GET https://conductscience.org/api/papers/v1/35637990/references?page=2